Loading
Diagnostic Medical Systems Stock: price and insider trades · France
1 insider bought €2.0M of shares over the last 90 days, the latest filed 27 Jul 2026.
Diagnostic Medical Systems: what insiders have been doing
This page follows insider dealings at Diagnostic Medical Systems as filed with AMF, a company from the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 2 insiders published 2 filings.
Open-market activity splits into 1 purchase totalling €2.0M and 1 sale totalling €2.0M; 1 insider sit on the buying side and 1 insider on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €2.0M, sold by Bpifrance Investissement and made public on 27 July 2026 (8.0% of market cap). On the buying side, the filings list 1 board member among the declarants.
The last purchase on record was published on 27 July 2026, which is 82 days ago.
With 2 filings in twelve months, the company is quieter than the median of 6 filings across the 316 companies we follow on the same exchange. Looking back to 2025, when coverage begins, insiders filed 1 purchase and 4 sales.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by AMF. They describe what insiders did and are not a recommendation.
Insider Decl.
5
Thresholds
n/a
Buy Volume
€2M
1 ops. · all time
Sell Volume
€2M
4 ops. · all time
Who traded when
BuySaleRegis Roche2 sales
BPIFRANCE iNVESTISSEMENT1 sale
Bpifrance Investissement SAS1 buy
Since the insiders bought
- -15.7%Entry €1.06 · Close 14 Oct 2026 €0.89
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 18,790 of 24,148 companies
32.5
score / 100
Value29
Quality36
FCF yld-10%
Earn yld-0.7%
EV/EBITDA12.4x
ROE4.5%
Gross mgn41%
Net mgn-0.3%
Debt/EBITDA5.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€0.88
Analyst consensus
1 analysts1.00/5
€2.20Target €2.20(+149%)€2.20
Income statement
Revenue€50.0M
Gross profit€20.4M41% margin
EBITDA€3.4M7% margin
Net income-€167k0.9% margin
Valuation
PER (trailing)44.2x
PER (forward)8.8x
P/Book1.2x
Beta0.73
Balance sheet & cash
Market cap€22.9M
Total debt€18.7M
Free Cash Flow-€2.4M
Debt / Equity91%
Profitability & ownership
ROE4.5%
ROA2.1%
% insiders30.0%
% institutions15.5%
Last declaration on 27 July 2026
Declarations5 total
1,680,672 shares@ €1.197.96% mcap100.0% of flowActionHors plateforme de négociationISIN FR00122024972026DD1128697
1,680,672 shares@ €1.197.96% mcap100.0% of flowActionHors plateforme de négociationISIN FR00122024972026DD1128701
Canonical exit: 21 Oct 2026 (T+90)
2,500 shares@ €0.991529.1% of flowActionEuronext Growth ParisISIN FR00122024972025DD1016086
2,900 shares@ €1.28343.7% of flowActionEuronext Growth ParisISIN FR00122024972025DD1016084
1,768 shares@ €1.314527.3% of flowActionEuronext Growth ParisISIN FR00122024972025DD1016085
5 of 5 declarations
About Diagnostic Medical Systems
DIAGNOSTIC MEDICAL SYSTEMS, now communicated under the DMS Group / DMS Imaging brand, is a French industrial company specializing in the design, development and manufacture of high-performance medical imaging systems. Listed on Euronext Growth Paris under ISIN FR0012202497 and ticker ALDMS, the company focuses on two core markets: digital radiology and bone densitometry. Its main production site is located in Gallargues-le-Montueux in southern France, giving the group a solid industrial footprint in France while supporting a broad international commercial reach.
DMS’ business model is built around two main product families. The first is digital radiology, where the company develops imaging systems for hospitals, radiology practices and imaging networks, including fixed radiography rooms, mobile radiology platforms and complementary diagnostic solutions. The second is bone densitometry, a segment in which DMS positions itself as a European reference. Its Medix and Stratos ranges are designed and manufactured in France and are supported by software and clinical tools intended to improve workflow efficiency and diagnostic accuracy. The company also highlights advanced features such as 3D-DXA, a technology that enhances bone analysis and body composition assessment.
Read moreShow less
From a market standpoint, DMS is a mid-cap industrial player with strong export exposure. The group states that it serves customers across all continents through a network of more than 140 national distributors, and that 75% of 2024 revenue came from outside France. That international footprint is a key part of its growth strategy. Financially, DMS reported €46.1 million of revenue in 2024, then €50.0 million in 2025, representing 9% organic growth. The company also posted €10 million of revenue in Q1 2026, confirming continued operating momentum.
A number of recent milestones reinforce the company’s strategic profile. In 2025, DMS secured FDA clearance for its !M1 mobile radiology system in the United States as part of its partnership with JPI Healthcare Solutions, marking a significant step in its North American expansion. The group also emphasizes its Imaging 2027 strategic plan, which aims to deliver profitable, sustainable growth through innovation, industrial execution and broader international penetration. Another notable feature is DMS’ niche leadership in Europe’s bone densitometry market, where it describes itself as the only European manufacturer in a field otherwise dominated by U.S. and South Korean competitors.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
